Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Fund News: Ray Dalio, John Paulson, Lansdowne Partners

Page 1 of 2

Bridgewater to Cut Jobs as Dalio Says Some Areas ‘Bloated’ (Bloomberg)
Bridgewater Associates, the world’s largest hedge fund manager, indicated it’s planning to cut jobs as parts of its business have become too large. The firm told clients in a letter that it has 1,700 employees, up from 1,100 five years ago and 150 in 2001, according to a person who saw the letter. The changes follow a shake-up in the management team that occurred earlier this year. The letter — written by founder Ray Dalio and his other top executives — called the changes “conducting a renovation” and described some of Bridgewater’s non-investment areas as “bloated, inefficient, and bureaucratic.”


Billionaire John Paulson Stays Bullish On Pharma As His Merger Strategy Hits The Skids (Forbes)
Billionaire hedge fund manager John Paulson remains bullish on the pharmaceutical sector and its prospects of consolidation, even as a raging debate on drug price gouging and tax-dodging merger deals hangs over the industry and cuts into the performance of his struggling hedge fund, Paulson & Co. Paulson’s biggest holdings heading into 2016 — Allergan, Mylan, Valeant Pharmaceuticals, Shire and Teva Pharmaceuticals — have all performed poorly, punishing returns. A short-to-medium turn in performance for Paulson hinges of a recovery of these battered-down stocks.

Lansdowne’s Roden Says Hedge-Fund Woes Not the Fault of ETFs (Bloomberg)
Hedge funds perform badly because their investment analysis has failed and not as a result of an increase in exchange-traded and quant funds, according to Stuart Roden, chairman of Lansdowne Partners. Blaming passive investing strategies and volatility for poor performance by hedge funds is a “bad excuse,” Roden said at the Legends 4 Legends alternative investment conference in Amsterdam on Thursday. “As a buyer of those products, anyone who tells you anything different is kind of fooling you.” His London-based firm manages $19 billion.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!